Closed Loop Medicine completes recruitment into clinical study that is required for regulatory submission of its insomnia product CLM-IN01


Closed Loop Medicine Ltd, a healthcare company focused on developing drug + digital combination products, the next generation of pharmaceutical products announces that it has completed recruitment for its critical clinical trial in the development of its combination product CLM-IN01 for insomnia.

The company successfully completed dosing of all required participants with its proprietary drug, despite the trial being conducted in the midst of a COVID-19 lockdown. 

The global sleep economy is expected to grow to $585 billion by 2024, yet very few solutions for insomnia are helping people sleep better. Insomnia is a condition that afflicts 10-15% of the adult population and is often a further complication in certain neurodegenerative conditions, cancer, anxiety, depression and women’s health. 

The combination products being developed by Closed Loop Medicine transform a patient’s care by integrating drug therapy and digitally delivered care solutions. 

Article sourced from: https://www.closedloopmedicine.com/news-item-11-completes-recruitment-into-clinical-study
Published on: 24.03.21

Contact us


(+44) 1223 496 000

Babraham Research Campus Ltd
Babraham Research Campus
CB22 3AT, United Kingdom

Press Enquiries

01223 813 557

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
; ;